vs
Side-by-side financial comparison of Hess Midstream LP (HESM) and INTEGRA LIFESCIENCES HOLDINGS CORP (IART). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $404.2M, roughly 1.1× Hess Midstream LP). On growth, Hess Midstream LP posted the faster year-over-year revenue change (2.1% vs -1.7%). Hess Midstream LP produced more free cash flow last quarter ($178.9M vs $-5.4M). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs 6.6%).
Hess Corporation is an American global independent energy company involved in the exploration and production of crude oil and natural gas. It was formed by the merger of Hess Oil and Chemical and Amerada Petroleum in 1968. Leon Hess was CEO from the early 1960s until 1995, after which his son John B Hess succeeded him as chairman and CEO. The company agreed to be acquired by rival oil company Chevron in October 2023, and the acquisition closed in July 2025.
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
HESM vs IART — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $404.2M | $434.9M |
| Net Profit | $93.3M | — |
| Gross Margin | — | 50.8% |
| Operating Margin | 62.2% | 5.3% |
| Net Margin | 23.1% | — |
| Revenue YoY | 2.1% | -1.7% |
| Net Profit YoY | 32.5% | — |
| EPS (diluted) | — | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $404.2M | $434.9M | ||
| Q3 25 | $420.9M | $402.1M | ||
| Q2 25 | $414.2M | $415.6M | ||
| Q1 25 | $382.0M | $382.7M | ||
| Q4 24 | $395.9M | $442.6M | ||
| Q3 24 | $378.5M | $380.8M | ||
| Q2 24 | $365.5M | $418.2M | ||
| Q1 24 | $355.6M | $368.9M |
| Q4 25 | $93.3M | — | ||
| Q3 25 | $97.7M | $-5.4M | ||
| Q2 25 | $90.3M | $-484.1M | ||
| Q1 25 | $71.6M | $-25.3M | ||
| Q4 24 | $70.4M | — | ||
| Q3 24 | $58.6M | $-10.7M | ||
| Q2 24 | $49.5M | $-12.4M | ||
| Q1 24 | $44.6M | $-3.3M |
| Q4 25 | — | 50.8% | ||
| Q3 25 | — | 51.5% | ||
| Q2 25 | — | 50.4% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 56.1% |
| Q4 25 | 62.2% | 5.3% | ||
| Q3 25 | 61.5% | 2.9% | ||
| Q2 25 | 62.8% | -123.4% | ||
| Q1 25 | 62.1% | -4.0% | ||
| Q4 24 | 61.4% | 8.0% | ||
| Q3 24 | 61.2% | -2.1% | ||
| Q2 24 | 60.8% | -0.7% | ||
| Q1 24 | 62.4% | 1.1% |
| Q4 25 | 23.1% | — | ||
| Q3 25 | 23.2% | -1.3% | ||
| Q2 25 | 21.8% | -116.5% | ||
| Q1 25 | 18.7% | -6.6% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 15.5% | -2.8% | ||
| Q2 24 | 13.5% | -3.0% | ||
| Q1 24 | 12.5% | -0.9% |
| Q4 25 | — | $-0.03 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-6.31 | ||
| Q1 25 | — | $-0.33 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $-0.14 | ||
| Q2 24 | — | $-0.16 | ||
| Q1 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $263.7M |
| Total DebtLower is stronger | $3.8B | $726.6M |
| Stockholders' EquityBook value | — | $1.0B |
| Total Assets | $4.4B | $3.6B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $263.7M | ||
| Q3 25 | $5.5M | $267.9M | ||
| Q2 25 | $4.5M | $253.6M | ||
| Q1 25 | $6.1M | $273.3M | ||
| Q4 24 | $4.3M | $273.6M | ||
| Q3 24 | $10.3M | $277.6M | ||
| Q2 24 | $99.6M | $296.9M | ||
| Q1 24 | $4.2M | $663.1M |
| Q4 25 | $3.8B | $726.6M | ||
| Q3 25 | — | $736.3M | ||
| Q2 25 | — | $745.9M | ||
| Q1 25 | — | $755.6M | ||
| Q4 24 | $3.5B | $760.5M | ||
| Q3 24 | — | $765.3M | ||
| Q2 24 | — | $770.2M | ||
| Q1 24 | — | $775.0M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.6B |
| Q4 25 | $4.4B | $3.6B | ||
| Q3 25 | $4.4B | $3.6B | ||
| Q2 25 | $4.4B | $3.7B | ||
| Q1 25 | $4.3B | $4.1B | ||
| Q4 24 | $4.2B | $4.0B | ||
| Q3 24 | $4.1B | $4.1B | ||
| Q2 24 | $4.1B | $4.1B | ||
| Q1 24 | $3.9B | $4.1B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.49× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $245.6M | $11.8M |
| Free Cash FlowOCF − Capex | $178.9M | $-5.4M |
| FCF MarginFCF / Revenue | 44.3% | -1.2% |
| Capex IntensityCapex / Revenue | 16.5% | 4.0% |
| Cash ConversionOCF / Net Profit | 2.63× | — |
| TTM Free Cash FlowTrailing 4 quarters | $728.2M | $-31.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $245.6M | $11.8M | ||
| Q3 25 | $258.9M | $40.9M | ||
| Q2 25 | $276.9M | $8.9M | ||
| Q1 25 | $202.4M | $-11.3M | ||
| Q4 24 | $258.5M | $50.7M | ||
| Q3 24 | $224.9M | $22.5M | ||
| Q2 24 | $271.6M | $40.4M | ||
| Q1 24 | $185.3M | $15.8M |
| Q4 25 | $178.9M | $-5.4M | ||
| Q3 25 | $178.9M | $25.8M | ||
| Q2 25 | $213.5M | $-11.2M | ||
| Q1 25 | $156.9M | $-40.2M | ||
| Q4 24 | $163.4M | $21.1M | ||
| Q3 24 | $132.6M | $-7.2M | ||
| Q2 24 | $207.7M | $10.7M | ||
| Q1 24 | $130.5M | $291.0K |
| Q4 25 | 44.3% | -1.2% | ||
| Q3 25 | 42.5% | 6.4% | ||
| Q2 25 | 51.5% | -2.7% | ||
| Q1 25 | 41.1% | -10.5% | ||
| Q4 24 | 41.3% | 4.8% | ||
| Q3 24 | 35.0% | -1.9% | ||
| Q2 24 | 56.8% | 2.6% | ||
| Q1 24 | 36.7% | 0.1% |
| Q4 25 | 16.5% | 4.0% | ||
| Q3 25 | 19.0% | 3.8% | ||
| Q2 25 | 15.3% | 4.8% | ||
| Q1 25 | 11.9% | 7.6% | ||
| Q4 24 | 24.0% | 6.7% | ||
| Q3 24 | 24.4% | 7.8% | ||
| Q2 24 | 17.5% | 7.1% | ||
| Q1 24 | 15.4% | 4.2% |
| Q4 25 | 2.63× | — | ||
| Q3 25 | 2.65× | — | ||
| Q2 25 | 3.07× | — | ||
| Q1 25 | 2.83× | — | ||
| Q4 24 | 3.67× | — | ||
| Q3 24 | 3.84× | — | ||
| Q2 24 | 5.49× | — | ||
| Q1 24 | 4.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HESM
| Gathering | $217.3M | 54% |
| Processing And Storage | $154.7M | 38% |
| Terminaling And Export | $32.2M | 8% |
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
